Safety and tolerability of methylphenidate in preschool children with ADHD

Tim Wigal, Laurence Greenhill, Shirley Chuang, James McGough, Benedetto Vitiello, Anne Skrobala, James Swanson, Sharon Wigal, Howard Abikoff, Scott Kollins, James McCracken, Mark A Riddle, Kelly Posner, Jaswinder Ghuman, Mark Davies, Ben Thorp, Annamarie Stehli

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To report on the safety and tolerability of methylphenidate (MPH) 3- to 5-year-old children with attention-deficit/hyperactivity disorder (ADHD) during 1 year of treatment. METHOD: Exactly 183 children (3-5 years old) entered a treatment study of MPH, consisting of a 1-week open-label lead-in (n = 183); a 5-week placebo-controlled, double-blind phase (n = 165); a 5-week double-blind, parallel phase (n = 114); and 10 months of open-label maintenance (n = 140 entered, 95 completed). Mean total daily MPH doses rose from the titration trial best dose, 14.1 (±8.1) mg/day, to 20.5 (±9.7) mg/day mean total daily dose at the end of maintenance. Pulse, blood pressure, and the presence of treatment emergent adverse events (AEs), parent and teacher AE ratings, and vital signs were recorded in each phase. RESULTS: Thirty percent of parents spontaneously reported moderate to severe AEs in all study phases after baseline. These included emotional outbursts, difficulty falling asleep, repetitive behaviors/thoughts, appetite decrease, and irritability. During titration, decreased appetite (χ = 5.4, p <.03), trouble sleeping (χ = 5.4, p <.03), and weight loss (χ = 4.0, p <.05) occurred statistically more often on MPH than on placebo. During maintenance, trouble sleeping and appetite loss persisted and other MPH-related AEs decreased. There were transient, one-time pulse and blood pressure elevations in five children. Twenty-one children (11%) discontinued because of drug-attributed AEs. CONCLUSIONS: Eleven percent of preschoolers discontinued treatment because of intolerable MPH AEs. Of the serious AEs reported, one occurred in baseline, two in lead-in, three in titration, one in parallel, and one in maintenance. Only one was possibly related to MPH. Copyright 2006

Original languageEnglish (US)
Pages (from-to)1294-1303
Number of pages10
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume45
Issue number11
DOIs
StatePublished - Nov 2006

Fingerprint

Methylphenidate
Preschool Children
Attention Deficit Disorder with Hyperactivity
Safety
Appetite
Maintenance
Blood Pressure
Placebos
Vital Signs
Therapeutics
Drug-Related Side Effects and Adverse Reactions
Weight Loss
Parents

Keywords

  • Adverse events
  • Attention-deficit/hyperactivity disorder
  • Methylphenidate
  • Preschoolers
  • Safety
  • Tolerability

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Developmental and Educational Psychology

Cite this

Safety and tolerability of methylphenidate in preschool children with ADHD. / Wigal, Tim; Greenhill, Laurence; Chuang, Shirley; McGough, James; Vitiello, Benedetto; Skrobala, Anne; Swanson, James; Wigal, Sharon; Abikoff, Howard; Kollins, Scott; McCracken, James; Riddle, Mark A; Posner, Kelly; Ghuman, Jaswinder; Davies, Mark; Thorp, Ben; Stehli, Annamarie.

In: Journal of the American Academy of Child and Adolescent Psychiatry, Vol. 45, No. 11, 11.2006, p. 1294-1303.

Research output: Contribution to journalArticle

Wigal, T, Greenhill, L, Chuang, S, McGough, J, Vitiello, B, Skrobala, A, Swanson, J, Wigal, S, Abikoff, H, Kollins, S, McCracken, J, Riddle, MA, Posner, K, Ghuman, J, Davies, M, Thorp, B & Stehli, A 2006, 'Safety and tolerability of methylphenidate in preschool children with ADHD', Journal of the American Academy of Child and Adolescent Psychiatry, vol. 45, no. 11, pp. 1294-1303. https://doi.org/10.1097/01.chi.0000235082.63156.27
Wigal, Tim ; Greenhill, Laurence ; Chuang, Shirley ; McGough, James ; Vitiello, Benedetto ; Skrobala, Anne ; Swanson, James ; Wigal, Sharon ; Abikoff, Howard ; Kollins, Scott ; McCracken, James ; Riddle, Mark A ; Posner, Kelly ; Ghuman, Jaswinder ; Davies, Mark ; Thorp, Ben ; Stehli, Annamarie. / Safety and tolerability of methylphenidate in preschool children with ADHD. In: Journal of the American Academy of Child and Adolescent Psychiatry. 2006 ; Vol. 45, No. 11. pp. 1294-1303.
@article{73d0e1510c424fafba88a3f9d6c027a0,
title = "Safety and tolerability of methylphenidate in preschool children with ADHD",
abstract = "OBJECTIVE: To report on the safety and tolerability of methylphenidate (MPH) 3- to 5-year-old children with attention-deficit/hyperactivity disorder (ADHD) during 1 year of treatment. METHOD: Exactly 183 children (3-5 years old) entered a treatment study of MPH, consisting of a 1-week open-label lead-in (n = 183); a 5-week placebo-controlled, double-blind phase (n = 165); a 5-week double-blind, parallel phase (n = 114); and 10 months of open-label maintenance (n = 140 entered, 95 completed). Mean total daily MPH doses rose from the titration trial best dose, 14.1 (±8.1) mg/day, to 20.5 (±9.7) mg/day mean total daily dose at the end of maintenance. Pulse, blood pressure, and the presence of treatment emergent adverse events (AEs), parent and teacher AE ratings, and vital signs were recorded in each phase. RESULTS: Thirty percent of parents spontaneously reported moderate to severe AEs in all study phases after baseline. These included emotional outbursts, difficulty falling asleep, repetitive behaviors/thoughts, appetite decrease, and irritability. During titration, decreased appetite (χ = 5.4, p <.03), trouble sleeping (χ = 5.4, p <.03), and weight loss (χ = 4.0, p <.05) occurred statistically more often on MPH than on placebo. During maintenance, trouble sleeping and appetite loss persisted and other MPH-related AEs decreased. There were transient, one-time pulse and blood pressure elevations in five children. Twenty-one children (11{\%}) discontinued because of drug-attributed AEs. CONCLUSIONS: Eleven percent of preschoolers discontinued treatment because of intolerable MPH AEs. Of the serious AEs reported, one occurred in baseline, two in lead-in, three in titration, one in parallel, and one in maintenance. Only one was possibly related to MPH. Copyright 2006",
keywords = "Adverse events, Attention-deficit/hyperactivity disorder, Methylphenidate, Preschoolers, Safety, Tolerability",
author = "Tim Wigal and Laurence Greenhill and Shirley Chuang and James McGough and Benedetto Vitiello and Anne Skrobala and James Swanson and Sharon Wigal and Howard Abikoff and Scott Kollins and James McCracken and Riddle, {Mark A} and Kelly Posner and Jaswinder Ghuman and Mark Davies and Ben Thorp and Annamarie Stehli",
year = "2006",
month = "11",
doi = "10.1097/01.chi.0000235082.63156.27",
language = "English (US)",
volume = "45",
pages = "1294--1303",
journal = "Journal of the American Academy of Child and Adolescent Psychiatry",
issn = "0890-8567",
publisher = "Elsevier Limited",
number = "11",

}

TY - JOUR

T1 - Safety and tolerability of methylphenidate in preschool children with ADHD

AU - Wigal, Tim

AU - Greenhill, Laurence

AU - Chuang, Shirley

AU - McGough, James

AU - Vitiello, Benedetto

AU - Skrobala, Anne

AU - Swanson, James

AU - Wigal, Sharon

AU - Abikoff, Howard

AU - Kollins, Scott

AU - McCracken, James

AU - Riddle, Mark A

AU - Posner, Kelly

AU - Ghuman, Jaswinder

AU - Davies, Mark

AU - Thorp, Ben

AU - Stehli, Annamarie

PY - 2006/11

Y1 - 2006/11

N2 - OBJECTIVE: To report on the safety and tolerability of methylphenidate (MPH) 3- to 5-year-old children with attention-deficit/hyperactivity disorder (ADHD) during 1 year of treatment. METHOD: Exactly 183 children (3-5 years old) entered a treatment study of MPH, consisting of a 1-week open-label lead-in (n = 183); a 5-week placebo-controlled, double-blind phase (n = 165); a 5-week double-blind, parallel phase (n = 114); and 10 months of open-label maintenance (n = 140 entered, 95 completed). Mean total daily MPH doses rose from the titration trial best dose, 14.1 (±8.1) mg/day, to 20.5 (±9.7) mg/day mean total daily dose at the end of maintenance. Pulse, blood pressure, and the presence of treatment emergent adverse events (AEs), parent and teacher AE ratings, and vital signs were recorded in each phase. RESULTS: Thirty percent of parents spontaneously reported moderate to severe AEs in all study phases after baseline. These included emotional outbursts, difficulty falling asleep, repetitive behaviors/thoughts, appetite decrease, and irritability. During titration, decreased appetite (χ = 5.4, p <.03), trouble sleeping (χ = 5.4, p <.03), and weight loss (χ = 4.0, p <.05) occurred statistically more often on MPH than on placebo. During maintenance, trouble sleeping and appetite loss persisted and other MPH-related AEs decreased. There were transient, one-time pulse and blood pressure elevations in five children. Twenty-one children (11%) discontinued because of drug-attributed AEs. CONCLUSIONS: Eleven percent of preschoolers discontinued treatment because of intolerable MPH AEs. Of the serious AEs reported, one occurred in baseline, two in lead-in, three in titration, one in parallel, and one in maintenance. Only one was possibly related to MPH. Copyright 2006

AB - OBJECTIVE: To report on the safety and tolerability of methylphenidate (MPH) 3- to 5-year-old children with attention-deficit/hyperactivity disorder (ADHD) during 1 year of treatment. METHOD: Exactly 183 children (3-5 years old) entered a treatment study of MPH, consisting of a 1-week open-label lead-in (n = 183); a 5-week placebo-controlled, double-blind phase (n = 165); a 5-week double-blind, parallel phase (n = 114); and 10 months of open-label maintenance (n = 140 entered, 95 completed). Mean total daily MPH doses rose from the titration trial best dose, 14.1 (±8.1) mg/day, to 20.5 (±9.7) mg/day mean total daily dose at the end of maintenance. Pulse, blood pressure, and the presence of treatment emergent adverse events (AEs), parent and teacher AE ratings, and vital signs were recorded in each phase. RESULTS: Thirty percent of parents spontaneously reported moderate to severe AEs in all study phases after baseline. These included emotional outbursts, difficulty falling asleep, repetitive behaviors/thoughts, appetite decrease, and irritability. During titration, decreased appetite (χ = 5.4, p <.03), trouble sleeping (χ = 5.4, p <.03), and weight loss (χ = 4.0, p <.05) occurred statistically more often on MPH than on placebo. During maintenance, trouble sleeping and appetite loss persisted and other MPH-related AEs decreased. There were transient, one-time pulse and blood pressure elevations in five children. Twenty-one children (11%) discontinued because of drug-attributed AEs. CONCLUSIONS: Eleven percent of preschoolers discontinued treatment because of intolerable MPH AEs. Of the serious AEs reported, one occurred in baseline, two in lead-in, three in titration, one in parallel, and one in maintenance. Only one was possibly related to MPH. Copyright 2006

KW - Adverse events

KW - Attention-deficit/hyperactivity disorder

KW - Methylphenidate

KW - Preschoolers

KW - Safety

KW - Tolerability

UR - http://www.scopus.com/inward/record.url?scp=33750498069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750498069&partnerID=8YFLogxK

U2 - 10.1097/01.chi.0000235082.63156.27

DO - 10.1097/01.chi.0000235082.63156.27

M3 - Article

C2 - 17028508

AN - SCOPUS:33750498069

VL - 45

SP - 1294

EP - 1303

JO - Journal of the American Academy of Child and Adolescent Psychiatry

JF - Journal of the American Academy of Child and Adolescent Psychiatry

SN - 0890-8567

IS - 11

ER -